Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CRBU

+ Watchlist+ Portfolio

Caribou Biosciences, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.34
52-Week Range
$0.31 – $2.49
Market Cap
$35.23M
P/E (TTM)
—
EPS (TTM)
-1.03
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.46
PEG Ratio
—
Return on Equity
-93.80%
Return on Assets
-42.34%
Gross Margin
0.00%
Operating Margin
-1140.56%
Profit Margin
0.00%
Current Ratio
4.97
Debt/Equity
0.34
Total Debt
$26.34M
Free Cash Flow
$-58.63M
Revenue Growth
-26.90%
Earnings Growth
—
Enterprise Value
$-33.23M

Market Snapshot

About

Caribou Biosciences, Inc. is a clinical-stage biotechnology company headquartered in Berkeley, California, developing off-the-shelf CAR-T cell therapies for the treatment of cancer. The company utilizes its proprietary CRISPR genome editing platform to develop next-generation cell therapies with improved anti-tumor activity and reduced manufacturing complexity. Caribou's lead programs target hematologic malignancies and are designed to be manufactured from healthy donor cells rather than a patient's own cells, potentially enabling faster treatment and lower costs. The company was founded by CRISPR pioneer Dr. Jennifer Doudna and has built significant intellectual property around CRISPR-based cellular therapies.